Live Breaking News & Updates on Nathaniel Massari

Stay updated with breaking news from Nathaniel massari. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Aytu BioPharma, Inc.: Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics

(0)
Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indications
Program initially targeting vascular Ehlers-Danlos Syndrome (vEDS), a rare inherited connective tissue disorder resulting in high morbidity and a significantly shortened life span with no FDA-approved treatments
Rumpus co-founders Christopher Brooke and Nathaniel Massari to join Aytu executive team with responsibility for AR101 program and development of pediatric onset rare disease pipeline
Company to host conference call today at 4:30 PM ET
ENGLEWOOD, CO / ACCESSWIRE / April 12, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the acquisition of a global license to AR101 (enzastaurin), a pivotal study-ready therapeutic candidate initially targeting the treatment of vascular Ehlers-Danlos ....

United States , Hal Dietz , Aytu Biopharma , Christopher Brooke , Josh Disbrow , Katie Wright , Lara Bloom , Nathaniel Massari , Josephine Grima , Sarah Mccabe , Nate Massari , Johns Hopkins University , Marfan Foundation , Stern Investor Relations Inc , Health Life Sciences , Wharton School , Endo Pharmaceuticals , Drug Administration , Princeton University , Denovo Biopharma , Exchange Commission , Aytu Biopharma Inc , University Of Pennsylvania , Securities Exchange , Ehlers Danlos Society , Diabetes Division At Astrazeneca ,

Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics

Press release content from Accesswire. The AP news staff was not involved in its creation.
Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics
April 12, 2021 GMT
Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indicationsProgram initially targeting vascular Ehlers-Danlos Syndrome (vEDS), a rare inherited connective tissue .
Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indicationsProgram initially targeting vascular Ehlers-Danlos Syndrome (vEDS), a rare inherited connective tissue .
Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indications ....

United States , Hal Dietz , Aytu Biopharma , Christopher Brooke , Josh Disbrow , Katie Wright , Lara Bloom , Nathaniel Massari , Josephine Grima , Sarah Mccabe , Nate Massari , Johns Hopkins University , Marfan Foundation , Stern Investor Relations Inc , Health Life Sciences , Wharton School , Endo Pharmaceuticals , Drug Administration , Princeton University , Denovo Biopharma , Exchange Commission , Aytu Biopharma Inc , University Of Pennsylvania , Securities Exchange , Ehlers Danlos Society , Diabetes Division At Astrazeneca ,

Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics

Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.

United States , Hal Dietz , Aytu Biopharma , Christopher Brooke , Josh Disbrow , Katie Wright , Lara Bloom , Nathaniel Massari , Josephine Grima , Sarah Mccabe , Nate Massari , Johns Hopkins University , Marfan Foundation , Stern Investor Relations Inc , Health Life Sciences , Wharton School , Endo Pharmaceuticals , Drug Administration , Princeton University , Denovo Biopharma , Exchange Commission , Aytu Biopharma Inc , University Of Pennsylvania , Securities Exchange , Ehlers Danlos Society , Diabetes Division At Astrazeneca ,

Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics

Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics
pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.

United States , Hal Dietz , Aytu Biopharma , Christopher Brooke , Josh Disbrow , Katie Wright , Lara Bloom , Nathaniel Massari , Josephine Grima , Sarah Mccabe , Nate Massari , Johns Hopkins University , Marfan Foundation , Stern Investor Relations Inc , Health Life Sciences , Wharton School , Endo Pharmaceuticals , Drug Administration , Princeton University , Denovo Biopharma , Exchange Commission , Aytu Biopharma Inc , University Of Pennsylvania , Securities Exchange , Ehlers Danlos Society , Diabetes Division At Astrazeneca ,

Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics

Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics
theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.

United States , Hal Dietz , Aytu Biopharma , Christopher Brooke , Josh Disbrow , Katie Wright , Lara Bloom , Nathaniel Massari , Josephine Grima , Sarah Mccabe , Nate Massari , Johns Hopkins University , Marfan Foundation , Stern Investor Relations Inc , Health Life Sciences , Wharton School , Endo Pharmaceuticals , Drug Administration , Princeton University , Denovo Biopharma , Exchange Commission , Aytu Biopharma Inc , University Of Pennsylvania , Securities Exchange , Ehlers Danlos Society , Diabetes Division At Astrazeneca ,